@conference{6c2343a56c944f438ac67ba33a6bf6ac,
title = "ONC201 in previously-irradiated pediatric H3 K27M-mutant glioma",
author = "Gardner, \{Sharon L.\} and Allen, \{Jeffrey C.\} and Zaky, \{Wafik Tharwat\} and Yazmin Odia and Doured Daghistani and Ziad Khatib and Koschmann, \{Carl Johannes\} and Dolly Aguilera and MacDonald, \{Tobey J.\} and Chi, \{Andrew S.\} and Rohinton Tarapore and Krystal Merdinger and Wolfgang Oster and Allen, \{Joshua E.\} and Soumen Khatua",
note = "10046 Background: ONC201 is the first DRD2 antagonist for clinical oncology. The recommended phase 2 dose (RP2D) of 625mg ONC201 orally once a week has been established in adult patients. ONC201 efficacy has been shown in high-grade glioma preclinical models and radiographic regressions with single agent ONC201 have been reported in adult recurrent H3 K27M-mutant glioma patients.; ASCO 2019 ; Conference date: 01-01-2019",
year = "2019",
doi = "10.1200/jco.2019.37.15\_suppl.10046",
language = "American English",
}